{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T13:06:26Z","timestamp":1774443986354,"version":"3.50.1"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>This phase I\/II study was conducted to evaluate the efficacy, safety and pharmacokinetics of streptozocin (STZ) in Japanese patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Twenty-two patients received up to 4\u00a0cycles of intravenous STZ at either 500\u00a0mg\/m2 once daily for 5 consecutive days every 6\u00a0weeks (daily regimen) or at 1000\u20131500\u00a0mg\/m2 once weekly for 6\u00a0weeks (weekly regimen). Tumor response was evaluated using the modified RECIST criteria ver. 1.1, and adverse events were assessed by grade according to the National Cancer Institute CTCAE (ver. 4.0).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Fourteen (63.6%) patients completed the study protocol. No patients had complete response; partial response in 2 (9.1%), stable disease in 17 (77.3%), non-complete response\/non-progressive disease in 2 (9.1%) and only 1 (4.5%) had non-evaluable disease. Excluding the latter, the response rate in the daily and weekly regimens was 6.7% (1\/15) and 16.7% (1\/6), respectively, with an overall response rate of 9.5% (2\/21). However, the best overall response in each patient showed that the disease control rate was 100%.<\/jats:p>\n                  <jats:p>Adverse events occurred in all 22 patients, including 17 grade 3 adverse events in 11 patients; however, no grade 4 or 5 adverse events were reported. Prophylactic hydration and antiemetic treatment reduced the severity and incidence of nephrotoxicity, nausea and vomiting. Plasma STZ concentrations decreased rapidly after termination of infusion, with a half-life of 32\u201340\u00a0min. Neither repeated administration nor dose increases affected pharmacokinetic parameters.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>STZ may be a useful option for Japanese patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyac048","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T09:08:42Z","timestamp":1649754522000},"page":"716-724","source":"Crossref","is-referenced-by-count":12,"title":["Phase I\/II study of streptozocin monotherapy in Japanese patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors"],"prefix":"10.1093","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9698-5507","authenticated-orcid":false,"given":"Izumi","family":"Komoto","sequence":"first","affiliation":[{"name":"Department of Surgery, Kansai Electric Power Hospital , Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiro","family":"Kokudo","sequence":"additional","affiliation":[{"name":"Hepato-Biliary-Pancreatic Surgery Division , Department of Surgery, , Tokyo, Japan"},{"name":"University of Tokyo Hospital , Department of Surgery, , Tokyo, Japan"},{"name":"National Center for Global Health and Medicine , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Aoki","sequence":"additional","affiliation":[{"name":"Hepato-Biliary-Pancreatic Surgery Division , Department of Surgery, , Tokyo, Japan"},{"name":"University of Tokyo Hospital , Department of Surgery, , Tokyo, Japan"},{"name":"Dokkyo Medical University Hospital , Tochigi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chigusa","family":"Morizane","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuhide","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Medicine and Bioregulatory Science , Graduate School of Medical Sciences, , Fukuoka, Japan"},{"name":"Kyushu University , Graduate School of Medical Sciences, , Fukuoka, Japan"},{"name":"Fukuoka Sanno Hospital , International University of Health and Welfare, Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Division of Hepato-Biliary-Pancreatic Surgery, Japanese Red Cross Medical Center , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological , Breast, Thyroid, and General Surgery, , Yamagata, Japan"},{"name":"Yamagata University Faculty of Medicine , Breast, Thyroid, and General Surgery, , Yamagata, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kansai Electric Power Hospital , Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Hepato-Biliary-Pancreatic Surgery Division , Department of Surgery, , Tokyo, Japan"},{"name":"University of Tokyo Hospital , Department of Surgery, , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9565-117X","authenticated-orcid":false,"given":"Shunsuke","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Ueno","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisato","family":"Igarashi","sequence":"additional","affiliation":[{"name":"Department of Medicine and Bioregulatory Science , Graduate School of Medical Sciences, , Fukuoka, Japan"},{"name":"Kyushu University , Graduate School of Medical Sciences, , Fukuoka, Japan"},{"name":"Igarashi Medical Clinic , Yamaguchi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takamasa","family":"Oono","sequence":"additional","affiliation":[{"name":"Department of Medicine and Bioregulatory Science , Graduate School of Medical Sciences, , Fukuoka, Japan"},{"name":"Kyushu University , Graduate School of Medical Sciences, , Fukuoka, Japan"},{"name":"National Hospital Organization Kyushu Cancer Center , Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Makuuchi","sequence":"additional","affiliation":[{"name":"Division of Hepato-Biliary-Pancreatic Surgery, Japanese Red Cross Medical Center , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Takamoto","sequence":"additional","affiliation":[{"name":"Division of Hepato-Biliary-Pancreatic Surgery, Japanese Red Cross Medical Center , Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Hirai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological , Breast, Thyroid, and General Surgery, , Yamagata, Japan"},{"name":"Yamagata University Faculty of Medicine , Breast, Thyroid, and General Surgery, , Yamagata, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Takeshita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological , Breast, Thyroid, and General Surgery, , Yamagata, Japan"},{"name":"Yamagata University Faculty of Medicine , Breast, Thyroid, and General Surgery, , Yamagata, Japan"},{"name":"Okitama Public General Hospital , Yamagata, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Imamura","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kansai Electric Power Hospital , Osaka, Japan"},{"name":"Neuroendocrine Tumor Center , Kansai Electric Power Hospital, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,4,12]]},"reference":[{"key":"2022093018253068000_ref1","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00535-014-0934-2","article-title":"Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis","volume":"50","author":"Ito","year":"2015","journal-title":"J Gastroenterol"},{"key":"2022093018253068000_ref2","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1186\/s12885-020-07581-y","article-title":"Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study","volume":"20","author":"Masui","year":"2020","journal-title":"BMC Cancer"},{"key":"2022093018253068000_ref3","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine Tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"2022093018253068000_ref4","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"New Engl J Med"},{"key":"2022093018253068000_ref5","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine Tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"New Engl J Med"},{"key":"2022093018253068000_ref6","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"2022093018253068000_ref7","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.2337\/diab.43.11.1326","article-title":"STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells","volume":"43","author":"Schnedl","year":"1994","journal-title":"Diabetes"},{"key":"2022093018253068000_ref8","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJM198011203032101","article-title":"Streptozocin alone compared with Streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma","volume":"303","author":"Moertel","year":"1980","journal-title":"New Engl J Med"},{"key":"2022093018253068000_ref9","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1056\/NEJM199202203260804","article-title":"Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma","volume":"326","author":"Moertel","year":"1992","journal-title":"New Engl J Med"},{"key":"2022093018253068000_ref10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00000421-199802000-00008","article-title":"Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma","volume":"21","author":"Rivera","year":"1998","journal-title":"Am J Clin Oncol"},{"key":"2022093018253068000_ref11","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/0016-5085(88)90670-1","article-title":"Prospective study of chemotherapy in patients with metastatic gastrinoma","volume":"94","author":"Schrenck","year":"1988","journal-title":"Gastroenterology"},{"key":"2022093018253068000_ref12","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/1097-0142(19900501)65:9<1883::AID-CNCR2820650902>3.0.CO;2-3","article-title":"Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors","volume":"65","author":"Eriksson","year":"1990","journal-title":"Cancer"},{"key":"2022093018253068000_ref13","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/(SICI)1097-0142(19990915)86:6<944::AID-CNCR8>3.0.CO;2-P","article-title":"Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma","volume":"86","author":"Cheng","year":"1999","journal-title":"Cancer"},{"key":"2022093018253068000_ref14","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1200\/JCO.2004.04.024","article-title":"Fluorouracil, doxorubicin, and streptozotocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas","volume":"22","author":"Kouvaraki","year":"2004","journal-title":"J Clin Oncol"},{"key":"2022093018253068000_ref15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s11523-012-0224-y","article-title":"Streptozocin-based chemotherapy is not history in neuroendocrine tumours","volume":"7","author":"Weatherstone","year":"2012","journal-title":"Target Oncol"},{"key":"2022093018253068000_ref16","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/sj.bjc.6605618","article-title":"Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours","volume":"102","author":"Turner","year":"2010","journal-title":"Br J Cancer"},{"key":"2022093018253068000_ref17","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00535-014-1006-3","article-title":"Streptozocin chemotherapy for advanced\/metastatic well-differentiated neuroendocrine tumors: an analysis of a multi-center survey in Japan","volume":"50","author":"Aoki","year":"2015","journal-title":"J Gastroenterol"},{"key":"2022093018253068000_ref18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2022093018253068000_ref19","first-page":"547","article-title":"Fate of streptozotocin (NSC-85998) in patients with advanced cancer","volume":"59","author":"Adolphe","year":"1975","journal-title":"Cancer Chemother Rep"},{"key":"2022093018253068000_ref20","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"key":"2022093018253068000_ref21","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1677\/ERC-09-0104","article-title":"Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710","volume":"16","author":"Dahan","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"2022093018253068000_ref22","doi-asserted-by":"crossref","first-page":"532","DOI":"10.14694\/EdBook_AM.2012.32.230","article-title":"Antiemetic use in oncology: updated guideline Recommendations from ASCO","author":"Basch","year":"2012","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2022093018253068000_ref23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.17925\/EOH.2012.08.4.217","article-title":"Optimising therapeutic options for patients with advanced pancreatic neuroendocrine tumours","volume":"8","author":"Yao","year":"2012","journal-title":"Eur Oncol Haematol"},{"key":"2022093018253068000_ref24","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.pan.2020.06.002","article-title":"Optimal strategy of systemic treatment for unresectable pancreatic neuroendocrine tumors based upon opinion of Japanese experts","volume":"20","author":"Ikeda","year":"2020","journal-title":"Pancreatology"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/52\/7\/716\/46214518\/hyac048.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/52\/7\/716\/46214518\/hyac048.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T19:45:41Z","timestamp":1664567141000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/52\/7\/716\/6566827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,12]]},"references-count":24,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,4,12]]},"published-print":{"date-parts":[[2022,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyac048","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7]]},"published":{"date-parts":[[2022,4,12]]}}}